Truist Securities Downgrades Pacira BioSciences to Hold, Raises Price Target to $36.5
Benzinga Newsdesk 3 weeks ago
Analyst RatingsNewsDowngradesPrice Target
Truist Securities analyst Anish Nikhanj downgrades Pacira BioSciences (NASDAQ:PCRX) from Buy to Hold and raises the price target from $31 to $36.5.
Truist Securities analyst Anish Nikhanj downgrades Pacira BioSciences (NASDAQ:PCRX) from Buy to Hold and raises the price target from $31 to $36.5.